Adlai Nortye Ltd., a clinical-stage biopharma focused on challenging cancer targets, has sharply reduced its losses alongside declining revenue tied to licensing shifts. Its novel drug candidates—an oral pan-RAS(ON) inhibitor, an antibody-drug conjugate targeting CEACAM5, and next-gen immunotherapies—are progressing with encouraging early clinical activity. Recent leadership appointments of industry veterans Dr. Tse and Dr. Ye signal increased operational rigor and strategic realignment. Despite meaningful cash burn from R&D investment, the firm maintains sufficient liquidity bolstered by recent collaborations and private placements. Upcoming trial readouts and partnership milestones will be pivotal against inherent clinical and regulatory risks.